Why the exact subtype changes what a Chinese team can discuss
Diffuse large B-cell lymphoma is a category, not a single uniform disease. The pathology report should state the specific diagnosis, and the biomarker results should show which markers were tested and what they found. Lymphoma includes Hodgkin and non-Hodgkin types, and the exact diagnosis matters when treatment is discussed. That is the reason a general 'lymphoma' summary is not enough for a meaningful review.
When you send records to a Chinese hospital or coordination team, the first useful step is confirming that the documents actually name the subtype. If the report says only 'large B-cell lymphoma' without further classification, the receiving clinician may need the original slides or blocks re-examined. That is a pathology question, not a coordination question, and it should be raised directly with the treating team.
A practical distinction: a subtype report answers 'what is this?', while a biomarker report answers 'what features does it have?'. Both are needed. Sending one without the other often produces a reply asking for the other, which adds a round of communication.
What a biomarker report should actually contain
Biomarker results are not a single number. They are a set of findings from tests such as immunohistochemistry, fluorescence in situ hybridisation, or molecular studies. The report should state which markers were tested, the method used, the result for each, and the reference range or interpretation where applicable.
If your current report lists results without the method or the laboratory's interpretation, ask the original pathology laboratory for the full report rather than a summary. A receiving clinician in China cannot assess a marker result without knowing how it was obtained.
Do not assume that a biomarker result automatically determines treatment. Biomarker findings inform discussion, but the treating team decides how they apply to an individual case. Your role before travel is to make sure the information is complete and legible, not to interpret it yourself.
Previous regimens and relapse history: the part patients often under-document
A Chinese lymphoma team reviewing a relapsed or refractory case will want to know what was given, when, at what dose, and how the disease responded. A list of drug names alone is usually insufficient. The useful record includes the regimen name or components, the number of cycles completed, the dates, the response assessment after treatment, and the reason treatment changed.
If you have had more than one line of therapy, organise the history chronologically. Each line should show the regimen, the outcome, and the reason for moving to the next. This is the document that lets a clinician understand whether the disease is primary refractory, relapsed after response, or something else.
Relapsed-disease options depend on this history. Without it, a records-based opinion can only be general. With it, the discussion can focus on what has already been tried and what questions remain.
- Regimen name or drug components, with dates and number of cycles.
- Response assessment after each line, including imaging or biopsy where available.
- Reason for stopping or changing treatment.
- Any adverse events that affected treatment decisions.
What a Chinese hospital can and cannot confirm from records alone
A records-based review can help a Chinese lymphoma team understand your case and indicate whether further assessment in China is worth considering. It cannot confirm hospital acceptance, treatment eligibility, or access to a specific therapy. Those decisions belong to the treating hospital and licensed clinicians after they have assessed the patient.
This distinction matters for planning. If you are asking about relapsed-disease options, the honest answer is that no remote review can promise a particular regimen or trial place. What it can do is identify whether your records are complete enough for a meaningful discussion and what additional information the hospital would need.
Ask the specific provider what its written review includes, who reviews the records, and what the output will be. Do not assume that a review fee covers hospital charges, tests, or treatment. Coordination fees and hospital medical fees are separate.
How to prepare the record set without over-sending
The goal is a focused, legible set that answers the receiving clinician's likely questions, not a complete archive. Start with the pathology report and biomarker results, then add the treatment history and the most recent imaging or response assessment. If the original slides or blocks are available, note that they can be requested; do not send them unless the hospital asks.
The order of the set matters as much as its contents. A clinician reading a relapsed diffuse large B-cell lymphoma file wants to move from diagnosis to treatment to current status without hunting for documents. If the pathology report sits at the back and the treatment history is scattered across discharge summaries, the reviewer spends the first pass reconstructing a timeline instead of assessing the case. A one-page cover sheet listing what is enclosed, in what order, and what is still missing does more for the review than an extra fifty pages of unlabelled scans.
Label each document with its date and its source laboratory or hospital. Reports from different institutions often use different formats and reference ranges, and an unlabelled biomarker result from an outside laboratory can be difficult to place in context. If a test was repeated at a second hospital, keep both versions and note which is more recent. Do not merge results from different dates into a single table without saying so.
Translation is a practical question worth raising early. Ask the hospital or coordination team whether it needs certified translation of the pathology and biomarker reports, or whether a working translation is enough for the first review. The answer affects how long preparation takes, so confirm it before you begin translating a large file. Keep the original-language documents alongside any translation; a clinician may want to check a specific term.
Avoid sending a complete archive in the first contact. A short summary with the key documents is more useful and respects the receiving team's time. If the hospital needs more, it will ask. Sending everything at once also makes it harder for the reviewer to see which documents you consider central to the question you are asking.
For an initial enquiry, a brief summary is enough. Explain how you can share records after first contact, and ask what format the hospital prefers, whether it wants scanned files or photographs, and whether there is a size limit on attachments. Do not send passport numbers, payment details, or a full medical archive at this stage.
One more distinction is worth keeping clear. Preparing a good record set is administrative work; it does not establish that the records are clinically complete or that the case is suitable for review in China. If the pathology report does not name the subtype, or the biomarker report lacks the method used, that gap is a clinical question for the treating team, not something a better folder can fix. Note the gap in your cover sheet and ask the hospital how it wants to handle it.
If you are unsure whether a document belongs in the set, the test is whether it changes what a clinician would understand about the diagnosis, the treatment already given, or the current status of the disease. Imaging reports and response assessments pass that test. Routine administrative paperwork does not. When in doubt, list the document on the cover sheet and let the hospital decide whether it needs the full version.
Questions to ask before committing to travel
Before planning travel, ask the hospital or coordination team a small number of specific questions. Does the review include a written opinion? Who provides it? What records are still missing? What would the next step be if the review suggests further assessment in China? These questions clarify the process without requiring you to commit to treatment.
If you are considering care in China for diffuse large B-cell lymphoma, the relevant reference page is the lymphoma treatment page, which explains the broader service context. Use it alongside this guide, not instead of it.
A free initial case review can check whether your available diagnosis, records, and main question are complete enough to suggest a relevant next step. It is not a diagnosis or a promise of acceptance. You can start with a short summary by the enquiry form, email, or WhatsApp, and share records after first contact.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.